Kherion Technology

MENU menu




Welcome to Kherion® Technology Limited, a biotech company looking beyond convention. 


Kherion Technology is a privately held biotechnology company headquartered in Cambridge, U.K.


Kherion Technology’s research focuses on cutting edge technology in immunotherapy treatment of autoimmunity and cancer.


Central to Kherion Technology’s vision on immunotherapy treatment of autoimmune diseases and cancer is increased efficacy, greater patient safety and fewer adverse side effects for patients than most existing products in the pharmaceutical market.




Chronic autoimmune diseases:  Current treatments, typically, rely on immune suppression and can be dangerous due to serious side-effects, such as life-threatening infections. In addition, immunosuppression is mostly limited to alleviating signs and symptoms but is largely ineffective in treating chronic autoimmune diseases.


Cancer:  Many new treatments operate on the basis of immune cell gene manipulation, such as chimeric antigen receptor T (CAR-T) cell therapy, which comes with its own set of issues to overcome. Today, cancer is seen more as a disease of molecular mechanisms caused by specific gene mutations than a disease of specific organs. Thus, for example, treatment for colorectal cancer may turn out to be useful in treating breast cancer.


Proprietary compounds of Kherion® Technology ‘work with’, rather than inhibit or block, the immune system to treat chronic autoimmune diseases and cancer.

Kherion Technology drug candidates: 


  • treat autoimmune diseases without the side effects of opportunistic infections or use of (humanized) monoclonal antibodies which can cause other autoimmune disorders,
  • provide effective cancer immunotherapy treatment without the need to remove immune cells in order to engineer them to target a specific cancer, then infuse those cells back into the patient and, at the same time, avoid dangerous side effects such as severe cytokine release syndrome (sCRS),
  • avoid potentially serious genotoxic effects (such as clonal dominance or transactivation of proto-oncogenes), which are displayed with viral vector-based therapeutic cancer vaccines, and
  • successfully counteract tumor-induced immunosuppression that inhibits antitumor cells, thus allowing the expansion of immune effector cells from hematopoietic progenitor cells, which leads to an antitumor response. 


James Patrick Mixon (CEO and Chairman)

Dr. James Patrick Mixon, Ph.D. is the CEO and Chairman at Kherion Technology Ltd. He has been instrumental in establishing the company as a skilful scientist and entrepreneur. He performed his research mainly in the fields of Molecular Virology and Infectious Diseases. Dr. Mixon has worked in the Department of Microbiology at Emory University (Atlanta, USA), Department of Pathology at Grady Memorial Hospital (Atlanta, USA) and the Rabies Unit within Institut Pasteur (Paris, France). Dr. Mixon received his Ph.D. in Molecular Virology from the University of Cambridge (Cambridge, U.K.).



Prof. Sir Alan Fersht (Chair of Scientific Advisory Board)

Sir Alan is a leading authority in the field of protein engineering. He obtained his BA in Natural Sciences and his Ph.D. from Cambridge University (Cambridge, U.K.). After a postdoctoral appointment in the U.S., he became a staff member at the MRC Laboratory of Molecular Biology and subsequently held a Visiting Professorship at Stanford University (Stanford, USA). In 1978, Sir Alan became Professor of Organic chemistry at Imperial College, London (London, U.K.), a post he held for ten years before moving back to Cambridge to take up a position as the Herchel Smith Professor of Organic Chemistry at Cambridge University and the Director of the MRC Centre for Protein Engineering. From October 2012 until October 2018, he had been Master of Gonville and Caius College, Cambridge.


Although now emeritus, Sir Alan is still fully active in research with long term funding, including research on protein folding, misfolding and disease; drug discovery; and structure-activity relationships of proteins involved in cancer and disease.

Prof. Tim Cox (Member of Scientific Advisory Board)

Timothy Cox is Professor of Medicine Emeritus at the University of Cambridge, Life Fellow of Sidney Sussex College and Honorary Consultant Physician at Addenbrooke’s Hospital, U.K.


After qualification at the London Hospital Medical College and clinical training in Oxford, U.K. the Royal Postgraduate Medical School, Hammersmith, London, he was a visiting scientist at the Massachusetts Institute of Technology USA and Sir William Dunn School in Oxford, U.K. With consultant posts in internal medicine, gastroenterology and haematology he has maintained a specialist clinical interest in inherited metabolic diseases, including lysosomal diseases. Professor Cox’s research interests are in therapeutic gene transfer and in molecular pathogenesis of sphingolipid diseases. The Cox Laboratory is supported by the U.K. Medical Research Council, the National Institute for Health Research and several charities. Professor Cox has published more than 260 original articles and is an Editor of the three-volume Oxford Textbook of Medicine - a Sixth edition is due for publication by OUP in 2016.

James Thomas Mixon (Non-Executive Director)

Mr. James Thomas Mixon received his MBA from Wharton Business School (University of Pennsylvania; Philadelphia, USA) in Corporate Finance. Prior to retirement, he had approximately 30 years of experience in the IBM, Corp. As a Financial Analyst, he coordinated the preparation, consolidation, and presentations of divisional annual operating budgets, strategic financial plans as well as realized routine and period financial results achieved vis-à-vis forecasts and operating budgets pertaining to profit and loss statements, manpower, and capital expenditures. Experience includes Computer Operating Systems Development, and Systems Engineering.


While on “faculty loan” from the IBM, Corp. to Hampton University (Hampton, Virginia, USA), he taught Theory and Practice of Managerial Finance, Computer Coding, and General Accounting.


Kherion Technology seeks “snake killers” who can read the ingredients on a chewing gum wrapper and unlock the secrets of the Universe.


Intrigued? Read on:


“I come from an environment where, if you see a snake, you kill it. At GM, if you see a snake, the first thing you do is go hire a consultant on snakes. Then you get a committee on snakes, and then you discuss it for a couple of years. The most likely course of action is -- nothing. You figure, the snake hasn't bitten anybody yet, so you just let [it] crawl around on the factory floor. We need to build an environment where the first [person] who sees the snake kills it.” – Thomas Moore, “The GM System Is Like A Blanket of Fog”, Fortune, February 15, 1988.


“Some people can read War and Peace and come away thinking it's a simple adventure story. Others can read the ingredients on a chewing gum wrapper and unlock the secrets of the Universe.” (Superman, 1978).


Sounds like you? Apply when positions become available, below.


Kherion Technology Limited

St John's Innovation Centre Ltd

Cowley Road




United Kingdom


Email: info{at}kherion-technology{dot}com